We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information on COVID-19, including guidance on the assessment and management of suspected UK cases.
Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.
How investigators and sponsors should manage clinical trials during COVID-19
Information on how UK companies can control risks when doing business in Mexico.
This guidance specifies the standards for the continuous monitoring and sampling of stack emissions.
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
Free and impartial help with money and pensions.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Information and guidance on a range of medical devices for users and patients.
Look up a trade mark to see if something identical or similar to your brand is already registered.
How to prepare and what to do if you’re affected by extreme weather and natural hazards while travelling or living abroad.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
Search for information about medicines including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs).
Advice and guidance on the health needs of migrant patients from Uruguay for healthcare practitioners.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Advice and guidance on the health needs of migrant patients from Colombia for healthcare practitioners.
Pharmacovigilance system requirements
How to use a randomised controlled trial to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.